JP2016519932A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016519932A5 JP2016519932A5 JP2016513127A JP2016513127A JP2016519932A5 JP 2016519932 A5 JP2016519932 A5 JP 2016519932A5 JP 2016513127 A JP2016513127 A JP 2016513127A JP 2016513127 A JP2016513127 A JP 2016513127A JP 2016519932 A5 JP2016519932 A5 JP 2016519932A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- human
- sortase
- antibody
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019079111A JP6901154B2 (ja) | 2013-05-10 | 2019-04-18 | ソルターゼ（Ｓｏｒｔａｓｅ）を用いた生存細胞のタンパク質修飾 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361822092P | 2013-05-10 | 2013-05-10 | |
| US61/822,092 | 2013-05-10 | ||
| US201461943094P | 2014-02-21 | 2014-02-21 | |
| US61/943,094 | 2014-02-21 | ||
| PCT/US2014/037545 WO2014183066A2 (en) | 2013-05-10 | 2014-05-09 | Protein modification of living cells using sortase |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019079111A Division JP6901154B2 (ja) | 2013-05-10 | 2019-04-18 | ソルターゼ（Ｓｏｒｔａｓｅ）を用いた生存細胞のタンパク質修飾 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016519932A JP2016519932A (ja) | 2016-07-11 |
| JP2016519932A5 true JP2016519932A5 (enExample) | 2017-06-22 |
| JP6603209B2 JP6603209B2 (ja) | 2019-11-06 |
Family
ID=51867884
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016513127A Expired - Fee Related JP6603209B2 (ja) | 2013-05-10 | 2014-05-09 | ソルターゼ（Ｓｏｒｔａｓｅ）を用いた生存細胞のタンパク質修飾 |
| JP2019079111A Expired - Fee Related JP6901154B2 (ja) | 2013-05-10 | 2019-04-18 | ソルターゼ（Ｓｏｒｔａｓｅ）を用いた生存細胞のタンパク質修飾 |
| JP2021043795A Active JP7306731B2 (ja) | 2013-05-10 | 2021-03-17 | ソルターゼ（Ｓｏｒｔａｓｅ）を用いた生存細胞のタンパク質修飾 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019079111A Expired - Fee Related JP6901154B2 (ja) | 2013-05-10 | 2019-04-18 | ソルターゼ（Ｓｏｒｔａｓｅ）を用いた生存細胞のタンパク質修飾 |
| JP2021043795A Active JP7306731B2 (ja) | 2013-05-10 | 2021-03-17 | ソルターゼ（Ｓｏｒｔａｓｅ）を用いた生存細胞のタンパク質修飾 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US10260038B2 (enExample) |
| EP (2) | EP2994530A4 (enExample) |
| JP (3) | JP6603209B2 (enExample) |
| AU (3) | AU2014262469B2 (enExample) |
| WO (1) | WO2014183066A2 (enExample) |
Families Citing this family (115)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2726494B1 (en) | 2011-06-28 | 2017-01-04 | Whitehead Institute For Biomedical Research | Using sortases to install click chemistry handles for protein ligation |
| US10260038B2 (en) | 2013-05-10 | 2019-04-16 | Whitehead Institute For Biomedical Research | Protein modification of living cells using sortase |
| EP3693398A1 (en) | 2013-05-10 | 2020-08-12 | Whitehead Institute for Biomedical Research | In vitro production of red blood cells with sortaggable proteins |
| EP3049442A4 (en) * | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| US10556024B2 (en) | 2013-11-13 | 2020-02-11 | Whitehead Institute For Biomedical Research | 18F labeling of proteins using sortases |
| BR112016011195A2 (pt) | 2013-11-18 | 2017-09-19 | Rubius Therapeutics Inc | Células eritroides enucleadas e seus métodos de fabricação, composição farmacêutica e seu uso, uso de uma população de células eritroides, biorreator, mistura de células e dispositivo médico |
| US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
| US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| KR20200029627A (ko) | 2014-03-12 | 2020-03-18 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소 |
| US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| CN106456744A (zh) | 2014-04-01 | 2017-02-22 | 鲁比厄斯治疗法股份有限公司 | 用于免疫调节的方法和组合物 |
| US20150307620A1 (en) * | 2014-04-16 | 2015-10-29 | University Of Connecticut | Linked immunotherapeutic agonists that costimulate multiple pathways |
| WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| EP3194585A1 (en) * | 2014-07-21 | 2017-07-26 | Novartis AG | Sortase molecules and uses thereof |
| GB201417288D0 (en) * | 2014-09-30 | 2014-11-12 | Univ Dundee | Cysteine labelling |
| US10053683B2 (en) * | 2014-10-03 | 2018-08-21 | Whitehead Institute For Biomedical Research | Intercellular labeling of ligand-receptor interactions |
| EP3789403A1 (en) * | 2014-11-11 | 2021-03-10 | MedImmune Limited | Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof |
| JP6800154B2 (ja) | 2014-12-17 | 2020-12-16 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 結合形成酵素の活性アッセイ |
| BR112017010888A2 (pt) | 2014-12-17 | 2018-02-27 | Hoffmann La Roche | método para produzir um produto de conjugação enzimática de três polipeptídeos |
| MX394865B (es) * | 2015-02-12 | 2025-03-24 | Beyondspring Pharmaceuticals Inc | Uso de plinabulina en combinación con inhibidores de punto de control inmunitario |
| BR112017018770A2 (pt) * | 2015-03-02 | 2018-04-17 | Innovative Cellular Therapeutics CO., LTD. | redução da tolerância imunológica induzida por pd-l1 |
| EP3770807B1 (en) * | 2015-05-04 | 2023-11-01 | Smith, Andrew Dennis | Computer-assisted tumor response assessment and evaluation of the vascular tumor burden |
| WO2016177682A1 (en) | 2015-05-06 | 2016-11-10 | Snipr Technologies Limited | Altering microbial populations & modifying microbiota |
| US20200079860A1 (en) * | 2015-08-06 | 2020-03-12 | Memorial Sloan Kettering Cancer Center | Methods and compositions for tumor therapy |
| US11667691B2 (en) | 2015-08-07 | 2023-06-06 | Novartis Ag | Treatment of cancer using chimeric CD3 receptor proteins |
| JP2017043547A (ja) * | 2015-08-24 | 2017-03-02 | 国立研究開発法人理化学研究所 | ポリペプチドを結合した成長因子及びその利用 |
| CN108138158B (zh) * | 2015-09-25 | 2021-11-09 | 豪夫迈·罗氏有限公司 | 可溶性分选酶a |
| EP3353310B1 (en) | 2015-09-25 | 2020-04-29 | H. Hoffnabb-La Roche Ag | Process for producing thioesters employing a sortase a |
| JP6998863B2 (ja) | 2015-09-25 | 2022-02-04 | エフ．ホフマン－ラ ロシュ アーゲー | 深共融溶媒におけるソルターゼａを利用したアミド基転移 |
| US12048753B2 (en) | 2015-10-01 | 2024-07-30 | Whitehead Institute For Biomedical Research | Labeling of antibodies |
| PT3370768T (pt) | 2015-11-03 | 2022-04-21 | Janssen Biotech Inc | Anticorpos que se ligam especificamente ao pd-1 e seus usos |
| CN105400773B (zh) * | 2015-12-14 | 2018-06-26 | 同济大学 | 应用于大规模筛选癌症基因的CRISPR/Cas9富集测序方法 |
| CN108697733A (zh) | 2016-01-11 | 2018-10-23 | 鲁比厄斯治疗法股份有限公司 | 与癌症适应症的多模式治疗性细胞体系有关的组合物和方法 |
| CN105821039B (zh) * | 2016-03-09 | 2020-02-07 | 李旭 | 联合免疫基因抑制HBV复制的特异性sgRNA、表达载体及其应用 |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
| CN109475524A (zh) | 2016-06-06 | 2019-03-15 | 万春药业公司 | 用于减少中性粒细胞减少症的组合物和方法 |
| JP7295795B2 (ja) * | 2016-07-29 | 2023-06-21 | ジュノー セラピューティクス インコーポレイテッド | 免疫調節ポリペプチドならびに関連する組成物および方法 |
| CN110023489A (zh) * | 2016-08-29 | 2019-07-16 | Pdi医药发展国际股份公司 | 提供治疗活性细胞产物 |
| EP4372002A3 (en) * | 2016-09-14 | 2024-08-14 | The Trustees Of The University Of Pennsylvania | Proximity-based sortase-mediated protein purification and ligation |
| WO2018068201A1 (en) * | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
| EP3532075A4 (en) * | 2016-10-27 | 2020-07-08 | Intima Bioscience, Inc. | VIRAL METHODS OF MANUFACTURING GENETICALLY MODIFIED CELLS |
| WO2018085208A1 (en) | 2016-11-02 | 2018-05-11 | The Research Foundation For The State University Of New York | Methods of inhibiting viruses using compositions targeting tsg101-ubiquitin interaction |
| BR112019011138A2 (pt) | 2016-12-02 | 2019-10-01 | Rubius Therapeutics, Inc. | composições e métodos relacionados com sistemas celulares para penetração em tumores sólidos |
| WO2018129381A1 (en) | 2017-01-06 | 2018-07-12 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
| US20190375815A1 (en) * | 2017-01-31 | 2019-12-12 | Novartis Ag | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
| KR20190109479A (ko) | 2017-02-01 | 2019-09-25 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 호중구감소증의 감소 방법 |
| WO2018144966A1 (en) * | 2017-02-06 | 2018-08-09 | The Board Of Trustees Of The Leland Stanford Junior University | Bioconjugation methods for targeted in situ therapeutic delivery |
| CN110520522A (zh) | 2017-02-17 | 2019-11-29 | 鲁比厄斯治疗法股份有限公司 | 功能化红系细胞 |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| WO2018161026A1 (en) * | 2017-03-03 | 2018-09-07 | Obsidian Therapeutics, Inc. | Il15 compositions and methods for immunotherapy |
| BR112019018915A2 (pt) | 2017-03-15 | 2020-04-14 | Pandion Therapeutics Inc | imunotolerância direcionada |
| AU2018273914A1 (en) | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
| WO2019017937A1 (en) | 2017-07-19 | 2019-01-24 | Rubius Therapeutics, Inc. | COMPOSITIONS AND METHODS ASSOCIATED WITH MULTIMODAL THERAPEUTIC CELLULAR SYSTEMS FOR THE TREATMENT OF CARDIOMETABOLIC DISEASE |
| WO2019017940A1 (en) | 2017-07-19 | 2019-01-24 | Rubius Therapeutics, Inc. | COMPOSITIONS AND METHODS ASSOCIATED WITH MULTIMODAL THERAPEUTIC CELLULAR SYSTEMS FOR THE TREATMENT OF INFECTIOUS DISEASE |
| EP3672602A1 (en) | 2017-08-22 | 2020-07-01 | Rubius Therapeutics, Inc. | Lipid nanoparticle methods and compositions for producing engineered erythroid cells |
| US12227742B2 (en) | 2017-10-23 | 2025-02-18 | The Broad Institute, Inc. | Nucleic acid modifiers |
| WO2019090148A2 (en) | 2017-11-03 | 2019-05-09 | Rubius Therapeutics, Inc. | Compositions and methods related to therapeutic cell systems for tumor growth inhibition |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US20190201548A1 (en) | 2017-12-29 | 2019-07-04 | Rubius Therapeutics, Inc. | Gene editing and targeted transcriptional modulation for engineering erythroid cells |
| WO2019140116A2 (en) | 2018-01-10 | 2019-07-18 | Rubius Therapeutics, Inc. | Amplifiable rnas for therapeutic cell systems |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| SG11202008261WA (en) | 2018-03-08 | 2020-09-29 | Rubius Therapeutics Inc | Therapeutic cell systems and methods for treating cancer and infectious diseases |
| US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
| WO2019210280A1 (en) * | 2018-04-27 | 2019-10-31 | Casebia Therapeutics Limited Liability Partnership | Anti-bcma car-t-cells for plasma cell depletion |
| CN110499291B (zh) * | 2018-05-16 | 2023-11-24 | 上海赛比曼生物科技有限公司 | 无血清培养制备嵌合抗原受体t细胞的方法 |
| RU2677264C1 (ru) * | 2018-05-24 | 2019-01-16 | Общество с ограниченной ответственностью научно-технический центр "БиоКлиникум" (ООО НТЦ "БиоКлиникум") | Иммунотоксин для терапии рассеянного склероза, способ его получения и применения |
| US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
| EP3818072A1 (en) * | 2018-07-03 | 2021-05-12 | Technische Universität München | Means and methods for site-specific protein modification using transpeptidases |
| WO2020060496A1 (en) * | 2018-09-21 | 2020-03-26 | City University Of Hong Kong | Surface modified extracellular vesicles |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CA3154589A1 (en) | 2018-10-12 | 2020-04-16 | Mauro CASTELLARIN | Compositions and methods for switchable car t cells using surface-bound sortase transpeptidase |
| US20220023430A1 (en) * | 2018-11-13 | 2022-01-27 | Lipoxen Technologies Limited | Glycopolysialylation of blinatumomab |
| WO2020117852A1 (en) | 2018-12-03 | 2020-06-11 | Rubius Therapeutics, Inc. | Artificial antigen presenting cells including hla-e and hla-g molecules and methods of use |
| JP2022521738A (ja) | 2019-02-20 | 2022-04-12 | ルビウス セラピューティクス， インコーポレイテッド | 負荷可能な抗原提示ポリペプチドを含む操作された赤血球系細胞および使用方法 |
| EP3938784B1 (en) * | 2019-03-13 | 2026-04-29 | Merck Patent GmbH | Process for the preparation of lipidated proteinaceous structures |
| EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
| WO2020220016A1 (en) * | 2019-04-26 | 2020-10-29 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Artificial antigen presenting cells comprising ligands for nkg2d for expanding immune cells for immunotherapy |
| JP2022530130A (ja) | 2019-04-26 | 2022-06-27 | ルビウス セラピューティクス， インコーポレイテッド | 除核赤血球細胞を含む緩衝組成物 |
| AU2020279240A1 (en) | 2019-05-20 | 2021-12-23 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
| WO2020243006A1 (en) | 2019-05-24 | 2020-12-03 | Rubius Therapeutics, Inc. | Methods of generating enucleated erythroid cells |
| WO2021046451A1 (en) | 2019-09-06 | 2021-03-11 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| CN114651003A (zh) | 2019-09-10 | 2022-06-21 | 黑曜石疗法公司 | 用于可调调节的ca2-il15融合蛋白 |
| US20210147802A1 (en) | 2019-11-04 | 2021-05-20 | Rubius Therapeutics, Inc. | Methods of generating enucleated erythroid cells using taurine or hypotaurine |
| EP4055149A1 (en) | 2019-11-04 | 2022-09-14 | Rubius Therapeutics, Inc. | Methods of generating enucleated erythroid cells using myo-inositol |
| WO2021145821A1 (en) | 2020-01-13 | 2021-07-22 | Carmine Therapeutics Pte. Ltd. | Nucleic acid loaded red blood cell extracellular vesicles |
| EP4103696A1 (en) | 2020-02-10 | 2022-12-21 | Rubius Therapeutics, Inc. | Engineered erythroid cells including hla-g polypeptides and methods of use thereof |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| WO2021185359A1 (en) * | 2020-03-20 | 2021-09-23 | Westlake Therapeutics (Hangzhou) Co. Limited | Modified red blood cells and uses thereof for delivering agents |
| AU2021270347A1 (en) | 2020-05-11 | 2022-12-15 | Erytech Pharma | Red cell extracellular vesicles (RCEVs) containing cargoes and methods of use and production thereof |
| USD980069S1 (en) | 2020-07-14 | 2023-03-07 | Ball Corporation | Metallic dispensing lid |
| CN111848816B (zh) * | 2020-07-24 | 2021-06-08 | 斯普迈(北京)生物科技有限公司 | 融合蛋白及其用途 |
| US20230399616A1 (en) * | 2020-10-30 | 2023-12-14 | Westlake Therapeutics (Hangzhou) Co. Limited | Modified Red Blood Cells and Uses Thereof for Delivering Agents |
| CA3201499A1 (en) | 2020-11-13 | 2022-05-19 | Catamaran Bio, Inc. | Genetically modified natural killer cells and methods of use thereof |
| TW202241471A (zh) | 2021-01-08 | 2022-11-01 | 美商盧比亞斯治療公司 | 提高個體中NKp30陽性淋巴球的方法及其用途 |
| TW202241470A (zh) | 2021-01-08 | 2022-11-01 | 美商盧比亞斯治療公司 | 治療人類個體腫瘤之方法 |
| CN114763369A (zh) * | 2021-01-12 | 2022-07-19 | 正大天晴药业集团股份有限公司 | 脂肪肽链及Fab-脂肪链偶联物 |
| KR20230147105A (ko) | 2021-01-28 | 2023-10-20 | 진콴텀 헬스케어 (쑤저우) 씨오., 엘티디. | 리가제 융합 단백질 및 그 응용 |
| US12168551B2 (en) | 2021-03-01 | 2024-12-17 | Ball Corporation | Metal container and end closure with seal |
| TW202304482A (zh) | 2021-03-14 | 2023-02-01 | 美商盧比亞斯治療公司 | 於個體中增加nkg2d陽性淋巴球之方法及其用途 |
| CN117202894A (zh) | 2021-03-31 | 2023-12-08 | 胭脂红治疗私人有限公司 | 负载至少两个不同核酸的细胞外囊泡 |
| EP4319751A4 (en) | 2021-04-09 | 2025-02-26 | Beyondspring Pharmaceuticals, Inc. | THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS |
| TW202317179A (zh) | 2021-06-03 | 2023-05-01 | 美商盧比亞斯治療公司 | 在個體中治療ｈｐｖ１６－陽性或ｈｐｖ１６－相關的癌症之方法 |
| WO2023284742A1 (en) * | 2021-07-13 | 2023-01-19 | Westlake Therapeutics (Hangzhou) Co. Limited | Cells modified by conjugated n-terminal glycine and uses thereof |
| MX2024006897A (es) * | 2021-12-10 | 2024-06-20 | Georgiamune Inc | Moduladores de polipeptidos. |
| CN118786207A (zh) * | 2022-01-12 | 2024-10-15 | 西湖生物医药科技(上海)有限公司 | 经修饰的细胞及其用途 |
| GB202209518D0 (en) | 2022-06-29 | 2022-08-10 | Snipr Biome Aps | Treating & preventing E coli infections |
| WO2024067295A1 (zh) * | 2022-09-28 | 2024-04-04 | 西湖生物医药科技(杭州)有限公司 | 修饰的红细胞及其用于递送药物的用途 |
| WO2024126289A1 (en) * | 2022-12-13 | 2024-06-20 | Evotec International Gmbh | Interferon-associated antigen binding proteins for use for the treatment or prevention of influenza virus infection |
| WO2024126293A1 (en) * | 2022-12-13 | 2024-06-20 | Evotec International Gmbh | Interferon-associated antigen binding proteins for use for the treatment or prevention of respiratory syncytial virus infection |
| WO2024126294A1 (en) * | 2022-12-13 | 2024-06-20 | Evotec International Gmbh | Interferon-associated antigen binding proteins for use for the treatment or prevention of parainfluenza virus infection |
| AU2024394385A1 (en) * | 2023-12-07 | 2026-06-11 | T-Curx Gmbh | Method of producing leukocytes expressing artificial antigen receptors |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5670132A (en) | 1994-09-20 | 1997-09-23 | Immunomedics, Inc. | Modified radioantibody fragments for reduced renal uptake |
| US5728369A (en) | 1994-10-05 | 1998-03-17 | Immunomedics, Inc. | Radioactive phosphorus labeling of proteins for targeted radiotherapy |
| US5891680A (en) | 1995-02-08 | 1999-04-06 | Whitehead Institute For Biomedical Research | Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12 |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| CA2365523A1 (en) | 1999-04-15 | 2000-10-26 | The Regents Of The University Of California | Identification of sortase gene |
| US20030119185A1 (en) | 2000-02-24 | 2003-06-26 | Xcyte Therapies, Inc. | Activation and expansion of cells |
| US20030235908A1 (en) | 2000-02-24 | 2003-12-25 | Xcyte Therapies, Inc. | Activation and expansion of cells |
| WO2002004030A2 (en) | 2000-07-06 | 2002-01-17 | Bristol-Myers Squibb Pharma Company | Stable radiopharmaceutical compositions |
| GB0025307D0 (en) | 2000-10-16 | 2000-11-29 | Celltech Chiroscience Ltd | Biological products |
| WO2002092134A1 (en) | 2001-05-14 | 2002-11-21 | Cell Genesys, Inc. | Lentiviral vectors encoding clotting factors for gene therapy |
| AU2003268546A1 (en) | 2002-09-06 | 2004-03-29 | Massachusetts Institute Of Technology | Lentiviral vectors, related reagents, and methods of use thereof |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| US6960473B2 (en) | 2003-02-27 | 2005-11-01 | Istituto Superiore Di Sanita | In vitro mass production of human erythroid cells from the blood of normal donors and thalassemic patients |
| JP2007521234A (ja) | 2003-08-12 | 2007-08-02 | ウィリアム エム ヤーブロー | 尋常性ざ瘡の治療薬及び使用方法 |
| US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| WO2005051976A2 (en) | 2003-11-20 | 2005-06-09 | Ansata Therapeutics, Inc. | Protein and peptide ligation processes and one-step purification processes |
| CA2566561C (en) | 2004-06-04 | 2013-01-08 | Universite Pierre Et Marie Curie - Paris Vi | A method for producing red blood cells |
| WO2006045064A2 (en) | 2004-10-20 | 2006-04-27 | Whitehead Institute For Biomedical Research | Cultured hematopoietic stem cells and method for expansion and analysis thereof |
| US8444973B2 (en) | 2005-02-15 | 2013-05-21 | Duke University | Anti-CD19 antibodies and uses in B cell disorders |
| WO2006127809A2 (en) | 2005-05-24 | 2006-11-30 | Whitehead Institute For Biomedical Research | Methods for expansion and analysis of cultured hematopoietic stem cells |
| EP1739165A1 (en) | 2005-06-29 | 2007-01-03 | Cellution Biotech B.V. | Method and apparatus for cultivating cells utilizing wave motion |
| BRPI0712729A2 (pt) | 2006-05-31 | 2013-07-02 | Nventa Biopharmaceuticals Corp | composiÇÕes hspe7 bioativas purificadas |
| US8398956B2 (en) | 2007-01-11 | 2013-03-19 | Immunomedics, Inc. | In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents |
| EP2155862A2 (en) | 2007-05-04 | 2010-02-24 | Whitehead Institute For Biomedical Research | Ex vivo expansion of human hematopoietic stem cells |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| EP2185188B1 (en) | 2007-08-22 | 2014-08-06 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
| US9757440B2 (en) | 2007-10-29 | 2017-09-12 | Trustees Of Dartmouth College | Method for treating cancer with Toxoplasma gondii vaccine |
| US8282942B2 (en) | 2007-10-29 | 2012-10-09 | Trustees Of Dartmouth College | Toxoplasma gondii vaccines and uses thereof |
| US20110038888A1 (en) | 2008-01-10 | 2011-02-17 | Peter Emtage | Adjuvant compositions comprising poly-ic and a cationic polymer |
| JP2011519557A (ja) | 2008-05-05 | 2011-07-14 | ウィルソン ウォルフ マニュファクチャリング コーポレイション | 細胞容器 |
| CA2730104A1 (en) | 2008-07-08 | 2010-01-14 | Wilson Wolf Manufacturing Corporation | Improved gas permeable cell culture device and method of use |
| US20110070154A1 (en) * | 2008-08-13 | 2011-03-24 | Hyde Roderick A | Artificial cells |
| EA201500417A1 (ru) | 2008-08-25 | 2015-11-30 | Эмплиммьюн, Инк. | Композиции антагонистов pd-1 и способы применения |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| CA2735456C (en) | 2008-08-26 | 2021-11-16 | City Of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| WO2010033913A1 (en) | 2008-09-22 | 2010-03-25 | Icb International, Inc. | Antibodies, analogs and uses thereof |
| WO2010036959A2 (en) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| JP2010115136A (ja) | 2008-11-12 | 2010-05-27 | Teruyuki Nagamune | Ｎ末端標識膜蛋白質の作製方法、及びｎ末端標識膜蛋白質を表層に有する細胞 |
| WO2010078376A2 (en) | 2008-12-30 | 2010-07-08 | Ventana Medical Systems, Inc. | Fc-specific polymer-conjugated antibodies and their diagnostic use |
| US8940501B2 (en) * | 2009-01-30 | 2015-01-27 | Whitehead Institute For Biomedical Research | Methods for ligation and uses thereof |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| JP2012521215A (ja) | 2009-03-26 | 2012-09-13 | アヴァリス・アクチエボラーグ | Ｎｋ細胞の増殖 |
| CA2772076A1 (en) | 2009-08-24 | 2011-03-10 | Baylor College Of Medicine | Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses |
| US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| US20110151551A1 (en) | 2009-12-22 | 2011-06-23 | Ge Healthcare Bio-Sciences Corp. | Bioreactors |
| JP6137596B2 (ja) | 2010-02-08 | 2017-05-31 | サンガモ セラピューティクス， インコーポレイテッド | 遺伝子操作された切断ハーフドメイン |
| AR080154A1 (es) | 2010-02-10 | 2012-03-14 | Immunogen Inc | Anticuerpos cd20 y su utilizacion |
| PL2539441T3 (pl) | 2010-02-22 | 2017-06-30 | Université Pierre Et Marie Curie (Paris 6) | Podłoże do hodowli komórkowej do wzrostu i różnicowania komórek linii hematopoetycznych |
| EP2539445B1 (en) | 2010-02-26 | 2018-03-21 | Cellectis | Use of endonucleases for inserting transgenes into safe harbor loci |
| CN102892786B (zh) | 2010-03-11 | 2016-03-16 | Ucb医药有限公司 | Pd-1抗体 |
| WO2011130624A2 (en) | 2010-04-16 | 2011-10-20 | Immune Disease Institute, Inc. | Sustained polypeptide expression from synthetic, modified rnas and uses thereof |
| US20130122043A1 (en) | 2010-04-20 | 2013-05-16 | Whitehead Institute For Biomedical Research | Modified polypeptides and proteins and uses thereof |
| EP3115373B1 (en) | 2010-09-08 | 2019-08-28 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Chimeric antigen receptors with an optimized hinge region |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2012142659A1 (en) * | 2011-04-19 | 2012-10-26 | Baker Idi Heart And Diabetes Institute Holdings Limited | Site-selective modification of proteins |
| US20130071414A1 (en) | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
| EP2726494B1 (en) | 2011-06-28 | 2017-01-04 | Whitehead Institute For Biomedical Research | Using sortases to install click chemistry handles for protein ligation |
| EP2546329A1 (en) | 2011-07-11 | 2013-01-16 | Lonza Cologne GmbH | Scale up of cell cultures |
| CN102559600A (zh) * | 2011-12-29 | 2012-07-11 | 上海交通大学医学院 | 一种人工抗原递呈细胞及其在nk细胞扩增中的应用 |
| WO2013132317A1 (en) | 2012-03-07 | 2013-09-12 | Aurigene Discovery Technologies Limited | Peptidomimetic compounds as immunomodulators |
| CA2870485A1 (en) | 2012-04-13 | 2013-10-17 | Whitehead Institute For Biomedical Research | Sortase-modified vhh domains and uses thereof |
| US20140030697A1 (en) | 2012-06-14 | 2014-01-30 | Massachusetts Institute Of Technology | Sortase-mediated modification of viral surface proteins |
| US9267127B2 (en) | 2012-06-21 | 2016-02-23 | President And Fellows Of Harvard College | Evolution of bond-forming enzymes |
| US9511350B2 (en) | 2013-05-10 | 2016-12-06 | Clean Diesel Technologies, Inc. (Cdti) | ZPGM Diesel Oxidation Catalysts and methods of making and using same |
| EP3693398A1 (en) | 2013-05-10 | 2020-08-12 | Whitehead Institute for Biomedical Research | In vitro production of red blood cells with sortaggable proteins |
| US10260038B2 (en) | 2013-05-10 | 2019-04-16 | Whitehead Institute For Biomedical Research | Protein modification of living cells using sortase |
| WO2015051188A1 (en) | 2013-10-02 | 2015-04-09 | Washington University | Heterocyclic molecules for biomedical imaging and therapeutic applications |
| US9878045B2 (en) | 2013-10-15 | 2018-01-30 | Regents Of The University Of Minnesota | Triorthogonal reagents for dual protein conjugation |
| US10556024B2 (en) | 2013-11-13 | 2020-02-11 | Whitehead Institute For Biomedical Research | 18F labeling of proteins using sortases |
| US10053683B2 (en) | 2014-10-03 | 2018-08-21 | Whitehead Institute For Biomedical Research | Intercellular labeling of ligand-receptor interactions |
| US12048753B2 (en) | 2015-10-01 | 2024-07-30 | Whitehead Institute For Biomedical Research | Labeling of antibodies |
| WO2020243006A1 (en) | 2019-05-24 | 2020-12-03 | Rubius Therapeutics, Inc. | Methods of generating enucleated erythroid cells |
-
2014
- 2014-05-09 US US14/890,296 patent/US10260038B2/en active Active
- 2014-05-09 WO PCT/US2014/037545 patent/WO2014183066A2/en not_active Ceased
- 2014-05-09 EP EP14795120.6A patent/EP2994530A4/en not_active Withdrawn
- 2014-05-09 EP EP22173120.1A patent/EP4119662A1/en not_active Withdrawn
- 2014-05-09 AU AU2014262469A patent/AU2014262469B2/en not_active Expired - Fee Related
- 2014-05-09 JP JP2016513127A patent/JP6603209B2/ja not_active Expired - Fee Related
-
2019
- 2019-02-15 US US16/277,721 patent/US12331311B2/en active Active
- 2019-04-11 US US16/381,654 patent/US11492590B2/en active Active
- 2019-04-18 JP JP2019079111A patent/JP6901154B2/ja not_active Expired - Fee Related
-
2020
- 2020-02-11 AU AU2020200962A patent/AU2020200962B2/en not_active Ceased
-
2021
- 2021-03-17 JP JP2021043795A patent/JP7306731B2/ja active Active
-
2022
- 2022-09-14 AU AU2022231702A patent/AU2022231702A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201770T1 (hr) | Nova imunoterapija protiv raznih vrsta karcinoma, uključujući gastrointestinalni karcinom i gastrični karcinom | |
| BR112022001923A2 (pt) | Proteína de ligação ao antígeno, ácido nucleico isolado, célula hospedeira recombinante, composição farmacêutica, método de produção da proteína de ligação ao antígeno | |
| JP2021534144A5 (enExample) | ||
| JP2021532114A5 (enExample) | ||
| UA105009C2 (uk) | Композиції та способи, призначені для спрямованого впливу антитіл на білок с5 системи комплементу | |
| JP2020530285A5 (enExample) | ||
| JP2012143232A5 (enExample) | ||
| NZ701444A (en) | Antibodies to matrix metalloproteinase 9 | |
| JP2014528696A5 (enExample) | ||
| HRP20220918T1 (hr) | Anti-transtiretinska antitijela | |
| PH12018502451A1 (en) | Brain delivery protein | |
| JP2014502253A5 (enExample) | ||
| RU2017107773A (ru) | Антитела, специфичные к ммр9 | |
| RU2015146419A (ru) | Выделение терапевтических доменов vnar, специфичных по отношению к мишени icosl | |
| EA201790341A1 (ru) | Анти-ск8 антитела для применения в лечении рака | |
| HRP20192262T1 (hr) | Nova imunoterapija protiv nekoliko tumora, kao što su rak pluća, uključujući mikrocelularni karcinom pluća (nsclc) | |
| JP2013511996A5 (enExample) | ||
| JP2017529870A5 (enExample) | ||
| JP2018507254A5 (enExample) | ||
| JO3188B1 (ar) | بروتينات رابطة لمولد الضد محددة لمكون p لنظير النشا بالمصل | |
| JP2018537117A5 (enExample) | ||
| EA201100741A1 (ru) | Антитела к модифицированным пептидам ифр-1/е человека | |
| JP2012523221A5 (enExample) | ||
| JP2020501521A5 (enExample) | ||
| HRP20211580T1 (hr) | Novi peptidi i kombinacije peptida za upotrebu u imunoterpiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova |